APAngela Pillatzki

Angela Pillatzki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angela Pillatzki has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Infectivity of recombinant Torque teno sus virus 1 in pigs coinfected with swine influenza virus

    by Md-Tariqul Islam, Angela Pillatzki, Brett Webb, Sheela Ramamoorthy

    Torque teno viruses (TTVs) are small non-enveloped DNA viruses that are ubiquitous among mammalian species. Although their pathogenic potential remains uncertain, TTVs can modulate host immunity and potentiate coinfecting pathogens or comorbid conditions. Progress in understanding TTV biology has been constrained by the absence of robust in vitro and in vivo experimental systems. To address these limitations, we investigated the infectivity of a recombinant swine TTV [Torque teno sus virus 1 (TTSuV1)] generated with a reverse genetics system in a snatch-farrowed piglet model. Additionally, we evaluated the impact of TTSuV1 coinfection on the pathogenesis and replication dynamics of swine influenza virus (SIV). Infection of piglets with the rescued TTSuV1 induced seroconversion and lymphopenia. Early infection was associated with reduced lymphocyte proliferative responses to mitogens and diminished or absent recall responses to viral antigens. TTSuV1 antigen was detected within immune cell populations by flow cytometry. Contrary to expectations, prior TTSuV1 infection did not significantly exacerbate SIV-associated clinical signs or pulmonary lesions. The use of a snatch-farrowed piglet model in combination with recombinant TTSuV1 derived from reverse genetics provides a controlled system for investigating TTV–host interactions. This approach represents a valuable tool for advancing mechanistic studies of TTV biology and its role in modulating coinfections.

  • Open Access

    Harnessing the Genetic Plasticity of Porcine Circovirus Type 2 to Target Suicidal Replication

    by Agm Rakibuzzaman, Pablo Piñeyro, Angela Pillatzki, Sheela Ramamoorthy

    Porcine circovirus type 2 (PCV2), the causative agent of a wasting disease in weanling piglets, has periodically evolved into several new subtypes since its discovery, indicating that the efficacy of current vaccines can be improved. Although a DNA virus, the mutation rates of PCV2 resemble RNA viruses. The hypothesis that recoding of selected serine and leucine codons in the PCV2b capsid gene could result in stop codons due to mutations occurring during viral replication and thus result in rapid attenuation was tested. Vaccination of weanling pigs with the suicidal vaccine constructs elicited strong virus-neutralizing antibody responses. Vaccination prevented lesions, body-weight loss, and viral replication on challenge with a heterologous PCV2d strain. The suicidal PCV2 vaccine construct was not detectable in the sera of vaccinated pigs at 14 days post-vaccination, indicating that the attenuated vaccine was very safe. Exposure of the modified virus to immune selection pressure with sub-neutralizing levels of antibodies resulted in 5 of the 22 target codons mutating to a stop signal. Thus, the described approach for the rapid attenuation of PCV2 was both effective and safe. It can be readily adapted to newly emerging viruses with high mutation rates to meet the current need for improved platforms for rapid-response vaccines.


  • Open Access

    Targeted Alteration of Antibody-Based Immunodominance Enhances the Heterosubtypic Immunity of an Experimental PCV2 Vaccine

    by Agm Rakibuzzaman, Oleksandr Kolyvushko, Gagandeep Singh, Peter Nara, Pablo Piñeyro, Estelle Leclerc, Angela Pillatzki, Sheela Ramamoorthy

    Despite the availability of commercial vaccines which can effectively prevent clinical signs, porcine circovirus type 2 (PCV2) continues to remain an economically important swine virus, as strain drift, followed by displacement of new subtypes, occurs periodically. We had previously determined that the early antibody responses to the PCV2 capsid protein in infected pigs map to immunodominant but non-protective, linear B cell epitopes. In this study, two of the previously identified immunodominant epitopes were mutated in the backbone of a PCV2b infectious clone, to rationally restructure the immunogenic capsid protein. The rescued virus was used to immunize 3-week-old weanling piglets, followed by challenge with a virulent heterologous PCV2d strain. As expected, immunodominant antibody responses to the targeted epitopes were abrogated in vaccinated pigs, while a broadening of the virus neutralization responses was detected. Vaccinated pigs were completely protected against challenge viral replication, had reduced microscopic lesions in lymphoid organs and gained significantly more body weight when compared to unvaccinated pigs. Thus, the experimental PCV2 vaccine developed was highly effective against challenge, and, if adopted commercially, can potentially slow down or eliminate new strain creation.


  • Open Access

    A Minimally Replicative Vaccine Protects Vaccinated Piglets Against Challenge With the Porcine Epidemic Diarrhea Virus

    by Gagandeep Singh, Pankaj Singh, Angela Pillatzki, Eric Nelson, Brett Webb, Steven Dillberger-Lawson, Sheela Ramamoorthy

    Porcine epidemic diarrhea virus (PEDV), is an economically important enteric coronavirus, with over a 90% mortality rate in neonatal piglets. The virus emerged in the US in 2013, resulting in severe production losses. Effective vaccine development against PEDV is a challenge. Inactivated vaccines are of questionable efficacy. Attenuated vaccines, while more effective, require a relatively long lead development time, are associated with safety concerns and are also unable to prevent new field outbreaks. To combine the safety and efficacy advantages of inactivated and attenuated PEDV vaccines, respectively, in this study, we tested the hypothesis that subjecting PEDV virions to heat treatment at 44°C for 10 min to reversibly unfold structural proteins, followed by exposure to RNAse to fragment the genome, would result in a vaccine preparation with intact viral structure/antigenicity but highly diminished replicative abilities. We expected the vaccine to be both safe and effective in a piglet challenge model. Following the heat and RNAse treatment, PEDV virions had an intact electron microscopic ultrastructure and were amplified only in the 3rd passage in Vero cells, indicating that diminished replication was achieved in vitro. Strong PEDV spike-protein specific and virus neutralizing antibody responses were elicited in vaccinated piglets. Upon challenge, all vaccinated pigs were protected against fecal viral shedding and intestinal pathology, while the unvaccinated controls were not. The vaccine virus was not detected in the fecal matter of vaccinated pigs prior to challenge; nor did they develop intestinal lesions. Thus, the described approach has significant promise in improving current approaches for PEDV immunization.


  • Open Access

    Efficacy of a Commercial PCV2a Vaccine with a Two-Dose Regimen Against PCV2d

    by Oleksandr Kolyvushko, Agm Rakibuzzaman, Angela Pillatzki, Brett Webb, Sheela Ramamoorthy

    Porcine circovirus type 2, the causative agent of porcine circovirus associated diseases (PCVAD), consists of three major genotypes PCV2a, 2b and 2d. Current commercial vaccines contain the first-identified PCV2a’s capsid protein or whole virions. Outbreaks of PCVAD, caused by the recently identified PCV2d in vaccinated herds have raised concerns regarding the efficacy of current PCV2a vaccines against PCV2d. Thus, the primary objective of this study was to assess the efficacy of a two-dose regimen for the recently reformulated Fostera PCV MetaStim vaccine, to determine if reformulation with the squalene oil adjuvant and two-dose regimen improves the threshold of protection enough to eliminate viremia in a vaccination and challenge model. Two groups of seven pigs each were vaccinated with the commercial vaccine or PBS, and challenged with the PCV2d virus. Strong pre-challenge virus neutralizing responses were detected against all three genotypes. Post-challenge viremia was not completely eliminated as expected but a 2 log10 mean reduction in viral load was achieved in vaccinated pigs. Vaccinated pigs had a mean score of 0 for pathological evaluation, while unvaccinated pigs had a score of 6.6. In conclusion, the reformulated Fostera PCV MetaStim PCV2a-based vaccine provided significant heterologous protection and was effective against PCV2d.